WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research
following the legalization of medical cannabis by several U.S. states.
While pioneers like British-based GW Pharmaceuticals plc
(NASDAQ: GWPH) have been actively studying cannabinoids since the
1990s, many North American companies haven’t started major research
until recent years with compounds just starting clinical trials.
Cannabis Technologies Inc.
(OTC: CANLF) (TSX-V: CAN) has been called the "junior GW" of the
cannabis industry with its growing pipeline of cannabinoid-based
therapies targeting a number of different conditions. On August 18,
2014, the company announced its second therapy, CTI-091, for the relief
of joint pain and swelling associated with arthritis and joint disease.
Preliminary studies indicated that CTI-091 suppresses the human
macrophage interleukin-6, a major inflammation biomarker, suggestive of
strong scientific evidence that cannabis extracts reverse the disease
progression. Once the company completes improvements to the delivery
systems efficacy, management plans to complete pre-clinical trials and
initiate Phase I clinical trials to assess the compound’s safety
Register here to receive free email updates on Cannabis Technologies developments: http://www.tdmfinancial.com/emailassets/canlf/canlf_landing.php
The market for effective arthritis treatments is enormous. With an
estimated 50 million U.S. citizens suffering from arthritis or related
diseases, several companies are targeting a piece of the estimated $35
billion global market. AstraZeneca plc’s (NYSE: AZN) and Amgen Inc.’s (NASDAQ: AMGN) brodalumab, for instance, is projected to peak at $0.5 billion to $1.5 billion in sales. This is a drop in the bucket compared to AbbVie Inc.’s (NYSE: ABBV) Humira, one of the leading sellers of all time regardless of indication.
"We are extremely pleased to announce a second therapy in our
expanding product pipeline," said Cannabis Technologies Inc. President
and CEO Craig Schneider. "The pain and arthritis therapy takes our
company to the next stage of development, reinforcing the proof of
concept of our Cannabinoid Drug Design platform. This platform is
designed to effectively identify and fast track new drug therapies."
Cannabinoid Platform Technology
Cannabis Technologies’ proprietary Cannabinoid Drug Design Platform
leverages the power of bioinformatics to identify individual compounds
from the cannabis plant that can be targeted to develop therapies for
specific diseases and conditions. While traditional drug development can
take years, management aims to utilize the platform to dramatically
reduce discovery time and accelerate development.
In addition to CTI-091, the company also leveraged the platform to
fast track the development of CTI-085 for the treatment of glaucoma. The
firm’s preclinical studies have shown that cannabinoids have the
ability to lower intraocular pressure ("IOP") in animal and could have
therapeutic potential in the treatment of glaucoma, without many of the
systemic side effects associated with other therapies.
ACADIA Pharmaceuticals Inc.’s (NASDAQ: ACAD) partnership with Allergan Inc. (NYSE: AGN) to develop Muscarinic
for the treatment of glaucoma demonstrates the strong demand for a safe
and viable treatment within the ~$5 billion per year industry. Many
existing treatment options for glaucoma – particularly in the late
stages – carry significant side effects for the patient.
Over the next twelve months, the company plans to announce numerous
additional therapies focusing on areas like metabolic disease, orphan
diseases and angiogenesis as it relates to cancer. These indications
address markets worth many billions of dollars per year and capturing
just a fraction of one of the markets could unlock significant value for
the ~$11 million micro-cap company.
Pre-commercialization partnerships could unlock incremental value as
the company’s drug development programs progress, too. While the
cannabis industry is somewhat controversial, many large pharmaceutical
companies are not opposed to partnerships. A great example is GW
Pharmaceuticals’ partnership with the $100 billion Bayer AG (OTC: BAYRY) for its cannabinoid-based Sativex.
Investors in the pharmaceutical industry may want to pay closer
attention to Cannabis Technologies’ – the “junior GW” – given its
innovative platform technology and growing pipeline of therapeutics
gearing up for Phase I clinical trials.
- Company Website
- OTC Markets Profile
Disclaimer: Except for the historical information presented herein,
matters discussed in this release contain forward-looking statements
that are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results, performance
or achievements expressed or implied by such statements. Emerging
Growth LLC is not registered with any financial or securities regulatory
authority, and does not provide nor claims to provide investment advice
or recommendations to readers of this release. Emerging Growth LLC may
from time to time have a position in the securities mentioned herein and
may increase or decrease such positions without notice. For making
specific investment decisions, readers should seek their own advice.
Emerging Growth LLC may be compensated for its services in the form of
cash-based compensation or equity securities in the companies it writes
about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/
SOURCE: Emerging Growth LLC